Aetram Research India: NIFTY PHARMA Weekly Sector Outlook
Nifty Pharma Remains Under Bearish Pressure; Recovery Needs 26,260 Strength, While 25,700 Weakness Could Deepen Selling - 10.10.2026
Current Market Price: 25,962.05
Market Prediction
- Nifty Pharma remains under corrective pressure after slipping beneath important moving-average zones and maintaining a descending price structure. RSI at 41.57 signals subdued momentum, CCI near -90 reflects continued weakness, while ADX at 26.56 confirms meaningful directional pressure. Recovery requires 26,260; failure below 25,700 could invite deeper selling interest.
Upcoming Events
- Quarterly pharmaceutical earnings could improve sentiment if margins and domestic growth strengthen (Positive Catalyst)
- Favourable USFDA approvals or product launches could support export-focused pharmaceutical companies (Positive Catalyst)
- Regulatory observations, pricing pressure or weak US generics performance may weigh on sentiment (Negative Catalyst)
Major Support and Resistance
- Support: 25,850, 25,700, 25,500
- Resistance: 26,260, 26,500, 26,610
Volume Analysis
- Volume remains moderate despite recent selling, indicating distribution without extreme panic participation. Recent declines have attracted selective buying near lower levels, but stronger volume expansion is necessary before any recovery can develop into sustained upward momentum.
Final Take Away
- Nifty Pharma remains technically vulnerable below its major moving-average cluster, with momentum indicators favouring sellers. Holding 25,700 can encourage stabilization, but a sustained move above 26,260 is required before the recovery structure becomes meaningfully stronger.
Next Week Prediction
- Nifty Pharma may stay pressured below 26,260 next week, with 25,700 acting as key defence; reclaiming 26,500 would materially improve the recovery structure and sentiment.
Scenario-Based Outlook
- Bullish Scenario: Above 26,260, price may move toward 26,500–26,610 zone
- Bearish Scenario: Below 25,700, downside risk toward 25,500–25,300 zone
- Neutral Scenario: Between 25,700–26,260, consolidation likely
Disclaimer: This research report is for informational purposes only. This is not an offer to buy or sell securities. Past performance is not indicative of future results. There is no guarantee of returns. Investments in securities are subject to market risks including loss of capital. Investors should consult their financial advisor before making any investment decisions.
